<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03579940</url>
  </required_header>
  <id_info>
    <org_study_id>17010</org_study_id>
    <secondary_id>H8H-JE-LAIE</secondary_id>
    <nct_id>NCT03579940</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan in Healthy Japanese and Caucasian Participants</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of lasmiditan in
      healthy Japanese and Caucasian participants. The study will also investigate how much
      lasmiditan gets into the bloodstream and how long it takes the body to get rid of lasmiditan
      when given to Japanese and Caucasians. The study will last up to 47 days for each
      participant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Actual">August 9, 2018</completion_date>
  <primary_completion_date type="Actual">August 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 20</time_frame>
    <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan in Each Period</measure>
    <time_frame>Period 1 and Period 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose; Period 3: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 36 and 48 hours postdose</time_frame>
    <description>PK: AUC(0-∞) of Lasmiditan in Each Period was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period</measure>
    <time_frame>Period 1 and Period 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose; Period 3: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 36 and 48 hours postdose</time_frame>
    <description>PK: Cmax of Lasmiditan in Each Period was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan - Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Japanese</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan - Caucasian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Caucasian</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of Placebo administered orally in up to one of three study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan - Caucasian</arm_group_label>
    <arm_group_label>Lasmiditan - Japanese</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo - Caucasian</arm_group_label>
    <arm_group_label>Placebo - Japanese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy Japanese (first generation) or Caucasian males or females, as
             determined by medical history and physical examination

          -  Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

        Exclusion Criteria:

          -  Have known allergies to lasmiditan, related compounds or any components of the
             formulation of lasmiditan

          -  Have previously received the investigational product in this study, withdrawn from
             this study, or received lasmiditan in any other study investigating lasmiditan

          -  Have an abnormal supine blood pressure at screening.

          -  Have a history of syncope, presyncope, uncontrolled vertigo, postural dizziness, or a
             risk of falls, as judged to be clinically significant by the investigator, or have
             orthostatic decreases in supine blood pressure of &gt;20 millimeters of mercury (mmHg),
             or have orthostatic decreases in diastolic blood pressure of &gt;10 mmHg at screening.

          -  Are women who are pregnant, lactating, or have a positive pregnancy test at screening
             or admission to the clinical research unit (CRU)

          -  Have donated blood of more than 500 milliliters (mL) within 1 month prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <results_first_submitted>November 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03579940/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03579940/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Crossover study with three study periods, each participant received single/repeated oral doses of 50, 100, 200, 400, or 2 X 200 milligram (mg) lasmiditan, placebo, or 2 X placebo, according to their assigned treatment sequence, on Day 1 of each Period. The washout period between dosing in consecutive study periods was approximately 72 hours.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Sequence 1: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Sequence 2: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Sequence 3: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: Placebo.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 2: Sequence 1: Japanese</title>
          <description>Participants received single, repeated oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 400 mg Lasmiditan and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: Sequence 2: Japanese</title>
          <description>Participants received single, repeated oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Sequence 3: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and repeated oral doses of placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 100 mg Lasmiditan Period 2: 400 mg Lasmiditan and Period 3: 2 X Placebo (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="P7">
          <title>Cohort 2: Sequence 4: Japanese</title>
          <description>Participants received single, repeated oral doses of Lasmiditan on day 1 of each treatment period as per the below dosing sequence.
Period 1: 200 mg Lasmiditan Period 2: 400 mg Lasmiditan and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3: Sequence 1: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 3: Sequence 2: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 3: Sequence 3: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: Placebo.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 3: Sequence 4: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Sequence 1: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Sequence 2: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: Sequence 3: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: Placebo.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2: Sequence 1: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 400 mg Lasmiditan and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2: Sequence 2: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2: Sequence 3: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 100 mg Lasmiditan Period 2: 400 mg Lasmiditan and Period 3: 2 X Placebo (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="B7">
          <title>Cohort 2: Sequence 4: Japanese</title>
          <description>Participants received single oral doses of Lasmiditan on day 1 of each treatment period as per the below dosing sequence.
Period 1: 200 mg Lasmiditan Period 2: 400 mg Lasmiditan and Period 3: 2 X 200 mg Lasmiditan (2 single doses administered 2 hours apart).</description>
        </group>
        <group group_id="B8">
          <title>Cohort 3: Sequence 1: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: Placebo Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 3: Sequence 2: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: Placebo and Period 3: 200 mg Lasmiditan.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 3: Sequence 3: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan and placebo on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: Placebo.</description>
        </group>
        <group group_id="B11">
          <title>Cohort 3: Sequence 4: Caucasian</title>
          <description>Participants received single oral doses of Lasmiditan on day 1 of each treatment period as per the below dosing sequence.
Period 1: 50 mg Lasmiditan Period 2: 100 mg Lasmiditan and Period 3: 200 mg Lasmiditan .</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="2"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
        <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.</description>
        <time_frame>Baseline up to Day 20</time_frame>
        <population>All enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Japanese</title>
            <description>Participants received single oral dose of placebo on day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Caucasian</title>
            <description>Participants received single oral dose of placebo on day 1.</description>
          </group>
          <group group_id="O3">
            <title>2 x Placebo: Japanese</title>
            <description>Participants received 2 x Placebo (2 single oral doses administered 2 hours apart) on day 1.</description>
          </group>
          <group group_id="O4">
            <title>50 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O5">
            <title>50 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O6">
            <title>100 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O7">
            <title>100 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O8">
            <title>200 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1</description>
          </group>
          <group group_id="O9">
            <title>200 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O10">
            <title>400 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 400 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O11">
            <title>2 X 200 mg Lasmiditan: Japanese</title>
            <description>Participants received 2 X 200 mg lasmiditan (2 single oral doses administered 2 hours apart) on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</title>
          <description>The number of participants with 1 or more SAEs considered by the investigator to be related to study drug administration is reported. Summaries of SAEs and other non-serious adverse events (AEs), regardless of causality, are located in the Reported Adverse Events module.</description>
          <population>All enrolled participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan in Each Period</title>
        <description>PK: AUC(0-∞) of Lasmiditan in Each Period was evaluated.</description>
        <time_frame>Period 1 and Period 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose; Period 3: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 36 and 48 hours postdose</time_frame>
        <population>All enrolled participants who received at least one dose of study drug and have evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O3">
            <title>100 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O4">
            <title>100 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O5">
            <title>200 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O6">
            <title>200 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O7">
            <title>400 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 400 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O8">
            <title>2 X 200 mg Lasmiditan: Japanese</title>
            <description>Participants received 2 X 200 mg lasmiditan (2 single oral doses administered 2 hours apart) on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Lasmiditan in Each Period</title>
          <description>PK: AUC(0-∞) of Lasmiditan in Each Period was evaluated.</description>
          <population>All enrolled participants who received at least one dose of study drug and have evaluable pharmacokinetic data.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362" spread="46"/>
                    <measurement group_id="O2" value="366" spread="78"/>
                    <measurement group_id="O3" value="791" spread="22"/>
                    <measurement group_id="O4" value="826" spread="70"/>
                    <measurement group_id="O5" value="1540" spread="26"/>
                    <measurement group_id="O6" value="2120" spread="50"/>
                    <measurement group_id="O7" value="3780" spread="32"/>
                    <measurement group_id="O8" value="3500" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period</title>
        <description>PK: Cmax of Lasmiditan in Each Period was evaluated.</description>
        <time_frame>Period 1 and Period 2: predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose; Period 3: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 36 and 48 hours postdose</time_frame>
        <population>All enrolled participants who received at least one dose of study drug and have evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O2">
            <title>50 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O3">
            <title>100 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O4">
            <title>100 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O5">
            <title>200 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O6">
            <title>200 mg Lasmiditan: Caucasian</title>
            <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O7">
            <title>400 mg Lasmiditan: Japanese</title>
            <description>Participants received single oral dose of 400 mg lasmiditan on day 1.</description>
          </group>
          <group group_id="O8">
            <title>2 X 200 mg Lasmiditan: Japanese</title>
            <description>Participants received 2 X 200 mg lasmiditan (2 single oral doses administered 2 hours apart) on day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period</title>
          <description>PK: Cmax of Lasmiditan in Each Period was evaluated.</description>
          <population>All enrolled participants who received at least one dose of study drug and have evaluable pharmacokinetic data.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" spread="35"/>
                    <measurement group_id="O2" value="52.4" spread="84"/>
                    <measurement group_id="O3" value="122" spread="18"/>
                    <measurement group_id="O4" value="101" spread="94"/>
                    <measurement group_id="O5" value="249" spread="39"/>
                    <measurement group_id="O6" value="309" spread="51"/>
                    <measurement group_id="O7" value="680" spread="40"/>
                    <measurement group_id="O8" value="519" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up To 20 days</time_frame>
      <desc>All enrolled participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo: Japanese</title>
          <description>Participants received single oral dose of placebo on day 1.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Caucasian</title>
          <description>Participants received single oral dose of placebo on day 1.</description>
        </group>
        <group group_id="E3">
          <title>2 x Placebo: Japanese</title>
          <description>Participants received 2 X Placebo (2 single oral doses administered 2 hours apart) on day 1.</description>
        </group>
        <group group_id="E4">
          <title>50 mg Lasmiditan: Japanese</title>
          <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E5">
          <title>50 mg Lasmiditan: Caucasian</title>
          <description>Participants received single oral dose of 50 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E6">
          <title>100 mg Lasmiditan: Japanese</title>
          <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E7">
          <title>100 mg Lasmiditan: Caucasian</title>
          <description>Participants received single oral dose of 100 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E8">
          <title>200 mg Lasmiditan: Japanese</title>
          <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E9">
          <title>200 mg Lasmiditan: Caucasian</title>
          <description>Participants received single oral dose of 200 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E10">
          <title>400 mg Lasmiditan: Japanese</title>
          <description>Participants received single oral dose of 400 mg lasmiditan on day 1.</description>
        </group>
        <group group_id="E11">
          <title>2 x 200 mg Lasmiditan: Japanese</title>
          <description>Participants received 2 X 200 mg lasmiditan (2 single oral doses administered 2 hours apart) on day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Details of the study and its results shall not be publicized in any form without prior consent of the Sponsor. Such approval is necessary to prevent premature disclosure of trade secrets and other confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

